Christophe Weber | President & CEO Andy Plump | President, R&D Milano Furuta | Chief Financial Officer PLAY LIST from the beginning FY2024 Q3 Earnings Announcement Important Notice Opening Remarks Presentation FY2024 Q3 YTD Results Driven by Growth & Launch Products, Continued VYVANSE Demand, and OPEX Efficiencies Strong Momentum of Growth & Launch Products +14.6% at CER FY2024 Q3 YTD Revenue: Growth & Launch Products More Than Offset Loss of Exclusivity Impact FY2024 Q3 YTD Core Operating Profit: Growth & Launch Products More Than Offset LOE Impact, with OPEX Benefitting from Efficiency Program FY2024 Q3 YTD Reported Operating Profit: Increase Reflects Growth in Core Operating Profit and Lower Impairment Compared to Prior Year Raising Full-Year Outlook: Expecting Revenue, Core O.P. & Margin Growth and Announcing Share Buyback up to JPY 100.0B FY2024 Forecast Upgrade Driven by Product Momentum, Slower Than Anticipated VYVANSE Generic Erosion in the U.S., & OPEX Savings Q&A SESSION Q&A SESSION1 Q&A SESSION2 Q&A SESSION3 Q&A SESSION4 Q&A SESSION5 Q&A SESSION6 Q&A SESSION7 Q&A SESSION8 Q&A SESSION9 Q&A SESSION10 Q&A SESSION11 APPENDIX @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ @ Back Next